Daiichi increases efforts to break into opioid market

Share this article:
Daiichi Sankyo blood thinner fails to wow
Daiichi increases efforts to break into opioid market

Daiichi Sankyo has doubled its attempts to break into the US prescription opioid market. The drugmaker announced Wednesday that it is collaborating with Charleston Laboratories in the development and commercialization of hydrocodone products, including CL-108, which is being considered for moderate-to-severe acute pain and reduction of opioid-induced nausea and vomiting.

Charleston's experimental treatment joins DS-7113, a Phase-III hydromorphone hydrochloride, which was already in Daiichi Sankyo's pipeline. Also known as Purdue Pharma's brand Dilaudid, the drug is not available in Japan. Daiichi Sankyo is hoping to be the first to enter that market. 

CL-108 combines promethazine, which is used to tamp down on symptoms such as motion sickness, the painkiller hydrocodone and the pain reliever acetaminophen.

The companies said in a statement that about 30% of hydrocodone patients suffer from opioid-induced nausea. Despite the furor over high opioid prescribing rates and an uptick in deaths associated with opiate use or abuse, the market for these drugs is seemingly elastic. Purdue Pharma's senior director of public affairs, Jim Heins, told MM&M in April that doctors need options “because one type of medication might become ineffective or might not be well tolerated by the patients, or they need to try something else.”

The $200-million cash deal includes up to $450 million in additional milestone payments to Charleston, and gives Daiichi US development rights. It also gives Daiichi Sankyo a firmer foothold in the opioid category—the company's marketable drug roster does not yet include a prescription opiate medication, and the Charleston deal means it now has one more potential opiate drug in its pipeline.

Daiichi Sankyo's spokesperson Kimberly Wix told MM&M in an email that while the company expects to promote Charleston's CL-108 to primary care physicians, the firms will also address specialists such as orthopedic surgeons, oral surgeons and emergency medical professionals.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...